## NBIX: Neurocrine Biosciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.9% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($139.52)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Neurocrine Biosciences (NBIX): Revisiting Valuation After a Year of Double-Digit Shareholder Returns**
- Source: Simply Wall Street | 20251214T200856 | Bullish | Relevance: 100%
- Neurocrine Biosciences (NBIX) has delivered steady double-digit returns for shareholders this year, with its stock up 11% year-to-date and 21% over the past year. Despite a perceived 38% undervaluation based on future growth, its current P/E ratio of 35.6x suggests investors are already paying a premium. The company's valuation hinges on strong future earnings and successful execution of clinical trials.

**2. Thrivent Financial for Lutherans Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX**
- Source: MarketBeat | 20251214T100856 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans reduced its stake in Neurocrine Biosciences, Inc. by 10.4% in the second quarter, selling 91,516 shares and now holding 787,299 shares valued at approximately $98.96 million. Despite this reduction, Neurocrine Biosciences reported a strong quarter, exceeding analyst expectations for EPS and revenue, and institutional investors collectively own 92.59% of the stock. Analysts currently maintain a "Moderate Buy" consensus rating with an average target price of $173.33 for NBIX.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Mizuho | $175 | $146 | +20% |
| 2025-12-11 | Stifel | $188 | $183 | +3% |
| 2025-12-08 | RBC Capital | $180 | $160 | +12% |
| 2025-12-05 | TD Cowen | $200 | $175 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Mizuho | main | Neutral |
| 2025-12-11 | Stifel | main | Buy |
| 2025-12-08 | RBC Capital | main | Outperform |
| 2025-12-05 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($1.77M) |
| Sells | 4 ($3.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 12.7% (-1.9%)
- Vanguard Group Inc: 9.7% (-1.0%)
- JPMORGAN CHASE & CO: 9.5% (+122.0%)
- Dodge & Cox Inc.: 5.6% (-0.2%)
- State Street Corpora: 4.4% (-2.7%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.2M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.27 indicates undervaluation relative to growth. Forward P/E 16.3x attractive for 32% earnings growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (3.4x), low leverage (D/E 0.42). Analyst sentiment positive (4 raises, avg +12%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.8B |
| Beta | 0.27 |
| 52W Range | $84.23 - $160.18 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.27 |
| Forward P/E | 16.3 |
| Current P/E | 21.5 |
| YoY Growth | 32.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.6% to -1.9% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.0pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.15x) but short-term weakness (below SMA20). RSI neutral at 48. OFD pattern: -FTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.95% (CS: 18) | Neutral |
| RSI_14 | 48.2 | Neutral |
| MACD Histogram | -0.25 | Bearish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 1.022x | Above |
| vs SMA200 | 1.151x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $148.74
- **Stop Loss:** $139.52 (6.2% risk)
- **Target:** $157.96 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 108
- **Position Value:** $16,063.92
- **Portfolio %:** 16.06%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-05 (Est: $2.41)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.07 | $2.17 | +4.9% |
| 2025Q2 | $1.50 | $1.65 | +9.6% |
| 2025Q1 | $1.09 | $0.70 | -36.0% |
| 2024Q4 | $1.93 | $1.69 | -12.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*